(19)
(11) EP 3 339 861 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
01.11.2023 Bulletin 2023/44

(45) Mention of the grant of the patent:
27.09.2023 Bulletin 2023/39

(21) Application number: 18154812.4

(22) Date of filing: 13.06.2013
(51) International Patent Classification (IPC): 
G01N 33/53(2006.01)
G01N 33/68(2006.01)
C12Q 1/00(2006.01)
(52) Cooperative Patent Classification (CPC):
G01N 33/689; G01N 2800/368

(54)

BIOMARKER TEST FOR PREDICTION OR EARLY DETECTION OF PREECLAMPSIA

BIOMARKERTEST ZUR VORHERSAGE ODER FRÜHERKENNUNG VON PRÄEKLAMPSIE

BIOMARQUEURS UTILISÉS POUR PRÉDIRE OU DÉTECTER PRÉCOCEMENT LA PRÉ-ÉCLAMPSIE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 15.06.2012 HU P1200368
10.09.2012 US 201261699193 P

(43) Date of publication of application:
27.06.2018 Bulletin 2018/26

(62) Application number of the earlier application in accordance with Art. 76 EPC:
16186083.8 / 3182126
13803743.7 / 2861989

(73) Proprietors:
  • Genesis Theranostix Korlatolt Felelossegu Tarsasag
    1061 Budapest (HU)
  • Semmelweis University
    1085 Budapest (HU)
  • The United States of America, As Represented by the Secretary, Dept. of Health & Human Services Office of Technology Transfer
    Bethesda, MD 20892-7660 (US)

(72) Inventors:
  • THAN, Nandor
    Grosse Pointe, MI 48236-1616 (US)
  • TARCA, Adi, L.
    Canton, MI 48188 (US)
  • JUHÁSZ, Gábor
    1117 Budapest (HU)
  • KÉKESI, Adrienna, Katalin
    1117 Budapest (HU)
  • MEIRI, Hamutal
    69121 Tel Aviv (IL)
  • PAPP, Zoltán
    1125 Budapest (HU)
  • ROMERO, Roberto
    Detroit, MI 48201 (US)

(74) Representative: Lengyel, Zsolt 
Danubia Patent & Law Office LLC Bajcsy-Zsilinszky út 16
1051 Budapest
1051 Budapest (HU)


(56) References cited: : 
WO-A1-2009/108073
US-A1- 2008 261 253
JP-A- 2008 241 704
   
  • LOCKWOOD C J; PAIDAS M J; LAPINSKI R; TAYLOR R: "Elevated maternal plasma beta-2-glycoprotein-1 (B2GP1) values precede the clinical onset of preeclampsia", AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY1995, vol. 172, no. 1 part 2, 427, 1995, page 378, XP009504149,
  • LIU C ET AL: "Proteomic analysis of human serum for Finding pathogenic factors and potential biomarkers in preeclampsia", PLACENTA, W.B. SAUNDERS, GB, vol. 32, no. 2, 9 November 2010 (2010-11-09), pages 168-174, XP028360520, ISSN: 0143-4004, DOI: 10.1016/J.PLACENTA.2010.11.007 [retrieved on 2010-11-17]
  • AUER J ET AL: "Serum profile in preeclampsia and intra-uterine growth restriction revealed by iTRAQ technology", JOURNAL OF PROTEOMICS, ELSEVIER, AMSTERDAM, NL, vol. 73, no. 5, 10 March 2010 (2010-03-10) , pages 1004-1017, XP026929961, ISSN: 1874-3919, DOI: 10.1016/J.JPROT.2009.12.014 [retrieved on 2010-01-14]
  • SCHOLL P F ET AL: "Maternal serum proteome changes between the first and third trimester of pregnancy in rural Southern Nepal", PLACENTA, W.B. SAUNDERS, GB, vol. 33, no. 5, 8 February 2012 (2012-02-08), pages 424-432, XP028478163, ISSN: 0143-4004, DOI: 10.1016/J.PLACENTA.2012.02.009 [retrieved on 2012-02-15]
  • T. VÁRKONYI ET AL: "Microarray Profiling Reveals That Placental Transcriptomes of Early-onset HELLP Syndrome and Preeclampsia Are Similar", PLACENTA, vol. 32, 1 February 2011 (2011-02-01), pages S21-S29, XP055217224, ISSN: 0143-4004, DOI: 10.1016/j.placenta.2010.04.014
  • NANDOR GABOR THAN ET AL: "Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia", FRONTIERS IN IMMUNOLOGY, vol. 9, 8 August 2018 (2018-08-08), XP055724102, DOI: 10.3389/fimmu.2018.01661
  • TROND M. MICHELSEN ET AL: "The human placental proteome secreted into the maternal and fetal circulations in normal pregnancy based on 4-vessel sampling", THE FASEB JOURNAL, vol. 33, no. 2, 18 October 2018 (2018-10-18), pages 2944-2956, XP055725694, US ISSN: 0892-6638, DOI: 10.1096/fj.201801193R
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).